US12054747B2 - Method of differentiating primordial germ cell into primordial follicle in vitro - Google Patents
Method of differentiating primordial germ cell into primordial follicle in vitro Download PDFInfo
- Publication number
- US12054747B2 US12054747B2 US17/253,518 US201917253518A US12054747B2 US 12054747 B2 US12054747 B2 US 12054747B2 US 201917253518 A US201917253518 A US 201917253518A US 12054747 B2 US12054747 B2 US 12054747B2
- Authority
- US
- United States
- Prior art keywords
- gonad
- primordial
- cells
- primordial germ
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 210000004602 germ cell Anatomy 0.000 title claims abstract description 149
- 238000000034 method Methods 0.000 title claims abstract description 112
- 238000000338 in vitro Methods 0.000 title claims abstract description 35
- 210000004027 cell Anatomy 0.000 claims abstract description 89
- 238000012258 culturing Methods 0.000 claims abstract description 69
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 47
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 47
- 239000001301 oxygen Substances 0.000 claims abstract description 47
- 210000000287 oocyte Anatomy 0.000 claims description 63
- 239000000262 estrogen Substances 0.000 claims description 50
- 229940011871 estrogen Drugs 0.000 claims description 50
- 239000003112 inhibitor Substances 0.000 claims description 36
- 210000002503 granulosa cell Anatomy 0.000 claims description 18
- 229940116355 PI3 kinase inhibitor Drugs 0.000 claims description 6
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims description 6
- 210000002149 gonad Anatomy 0.000 description 160
- 238000012744 immunostaining Methods 0.000 description 59
- 241000699666 Mus <mouse, genus> Species 0.000 description 53
- 239000002609 medium Substances 0.000 description 50
- 102000040945 Transcription factor Human genes 0.000 description 30
- 108091023040 Transcription factor Proteins 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 30
- 239000003163 gonadal steroid hormone Substances 0.000 description 26
- 210000001778 pluripotent stem cell Anatomy 0.000 description 26
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 25
- 210000001082 somatic cell Anatomy 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 23
- 239000007640 basal medium Substances 0.000 description 21
- 238000012758 nuclear staining Methods 0.000 description 19
- 239000002771 cell marker Substances 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 230000004720 fertilization Effects 0.000 description 16
- 238000010186 staining Methods 0.000 description 16
- 230000004069 differentiation Effects 0.000 description 15
- 239000012828 PI3K inhibitor Substances 0.000 description 14
- 108091007960 PI3Ks Proteins 0.000 description 14
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 239000012679 serum free medium Substances 0.000 description 14
- 102000038030 PI3Ks Human genes 0.000 description 13
- 210000004940 nucleus Anatomy 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 12
- 108010082025 cyan fluorescent protein Proteins 0.000 description 11
- 208000031513 cyst Diseases 0.000 description 11
- 235000013601 eggs Nutrition 0.000 description 11
- 210000003754 fetus Anatomy 0.000 description 10
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 10
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 9
- 108091005804 Peptidases Proteins 0.000 description 9
- 230000002706 hydrostatic effect Effects 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 102100037127 Developmental pluripotency-associated protein 3 Human genes 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
- 101000881866 Homo sapiens Developmental pluripotency-associated protein 3 Proteins 0.000 description 8
- 241000862969 Stella Species 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 210000002744 extracellular matrix Anatomy 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 108020004459 Small interfering RNA Proteins 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 230000035800 maturation Effects 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 239000004055 small Interfering RNA Substances 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 238000009395 breeding Methods 0.000 description 6
- 230000001488 breeding effect Effects 0.000 description 6
- 238000012136 culture method Methods 0.000 description 6
- 229960002258 fulvestrant Drugs 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 108010067306 Fibronectins Proteins 0.000 description 5
- 102000016359 Fibronectins Human genes 0.000 description 5
- 239000003098 androgen Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000000172 cytosol Anatomy 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 231100000535 infertility Toxicity 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 210000003518 stress fiber Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010011732 Cyst Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000034004 oogenesis Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 102000005969 steroid hormone receptors Human genes 0.000 description 4
- 108020003113 steroid hormone receptors Proteins 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 210000004420 female germ cell Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- -1 inositol phospholipid Chemical class 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000002783 mesonephros Anatomy 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- AEZPAUSGTAHLOQ-UHFFFAOYSA-N 4-[2-phenyl-5,7-bis(trifluoromethyl)-3-pyrazolo[1,5-a]pyrimidinyl]phenol Chemical compound C1=CC(O)=CC=C1C1=C2N=C(C(F)(F)F)C=C(C(F)(F)F)N2N=C1C1=CC=CC=C1 AEZPAUSGTAHLOQ-UHFFFAOYSA-N 0.000 description 2
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 2
- CPRAGQJXBLMUEL-UHFFFAOYSA-N 9-(1-anilinoethyl)-7-methyl-2-(4-morpholinyl)-4-pyrido[1,2-a]pyrimidinone Chemical compound C=1C(C)=CN(C(C=C(N=2)N3CCOCC3)=O)C=2C=1C(C)NC1=CC=CC=C1 CPRAGQJXBLMUEL-UHFFFAOYSA-N 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 239000012114 Alexa Fluor 647 Substances 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 208000017657 Menopausal disease Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010079855 Peptide Aptamers Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108010009711 Phalloidine Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108010008125 Tenascin Proteins 0.000 description 2
- 102100038126 Tenascin Human genes 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940061641 androsterone Drugs 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000021121 meiosis Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 108091008104 nucleic acid aptamers Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100035421 Forkhead box protein O3 Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000877681 Homo sapiens Forkhead box protein O3 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 101100391197 Mus musculus Foxo3 gene Proteins 0.000 description 1
- 101000687343 Mus musculus PR domain zinc finger protein 1 Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100024770 Probable ATP-dependent RNA helicase DDX4 Human genes 0.000 description 1
- 101710136296 Probable ATP-dependent RNA helicase DDX4 Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- LNZJMMAGCBQXBS-UHFFFAOYSA-N [4-(n-benzyl-4-nitroanilino)-1-methylpyrrol-2-yl]-pyrrolidin-1-ylmethanone Chemical compound CN1C=C(N(CC=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)C=C1C(=O)N1CCCC1 LNZJMMAGCBQXBS-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229950003628 buparlisib Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- TXLGPGWHIIHRHH-UHFFFAOYSA-N chembl520107 Chemical compound CC=1C(C=2C=CC(O)=CC=2)=NN(C=2C=CC(O)=CC=2)C=1C(C=C1)=CC=C1OCCN1CCCCC1 TXLGPGWHIIHRHH-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000001705 ectoderm cell Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 210000001368 germline stem cell Anatomy 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 238000010449 nuclear transplantation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
- C12N2501/392—Sexual steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/04—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from germ cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
Definitions
- the present invention relates to a method of differentiating a primordial germ cell into a primordial follicle in vitro.
- Priority is claimed on Japanese Patent Application No. 2018-117988, filed on Jun. 21, 2018, the content of which is incorporated herein by reference.
- Somatic cells that make up the body and germ cells that carry genetic information to a next generation are present in the living body.
- an egg which is a female germ cell is an important cell that plays a role in carrying out early development.
- the female germ cell in mammals undergoes meiosis after proliferation of primordial germ cells during an embryonic period, and undergoes most cell death almost at the same time as birth.
- Surviving oocytes form a primordial follicle with surrounding granulosa cells.
- the female germ cells decreases after peaking in primordial germ cells during the embryonic period, and after birth, while maintaining a limited number of oocytes, some of the cells are periodically activated to maintain an ovulation cycle.
- the primordial follicle is a base point of the ovulation cycle and is present in an ovarian cortex in a state where the oocytes are surrounded by a single layer of more flat granulosa cells.
- primordial follicles develop as primary follicles, secondary follicles, antral follicles, and Graffian follicles (mature follicles) to cause ovulation.
- the entire mechanism of maintenance and activation of primordial follicles has not yet been clarified.
- the establishment of an in vitro culture method for differentiating primordial follicles from primordial germ cells can be an approach to elucidate the mechanism of maintenance and activation of the primordial follicles. Furthermore, when such a culture method can be established, continuous oogenesis in vivo and in vitro becomes possible.
- the present invention has been made in view of the above circumstances, and provides a method of differentiating a primordial germ cell into a primordial follicle in vitro.
- a primordial follicle can be formed by culturing a primordial germ cell and a supporting cell adjacent to the primordial germ cell under a pressurized condition or a low oxygen concentration condition, and have completed the present invention.
- the present invention includes the following aspects.
- a method according to a first aspect of the present invention is a method of differentiating a primordial germ cell into a primordial follicle in vitro, the method including culturing a primordial germ cell and a supporting cell adjacent to the primordial germ cell under a pressurized condition or a low oxygen concentration condition.
- the culturing may be carried out under the pressurized condition and the low oxygen concentration condition.
- the culturing may be carried out in presence of a PI3 kinase inhibitor.
- the PI3 kinase inhibitor may be LY294002.
- the culturing may be carried out under a condition in which an influence of estrogen or a factor having a function similar to a function of the estrogen is eliminated.
- the low oxygen concentration condition may be a condition in which an oxygen concentration in a culture atmosphere is 7% or lower.
- the low oxygen concentration condition may be a condition in which an oxygen concentration in a culture atmosphere is 3% or higher and 7% or lower.
- the pressurized condition may be a condition of higher than 23 kPa and 40 kPa or lower.
- the pressurized condition may be a condition of 28 kPa or higher and 38 kPa or lower.
- the obtained primordial follicle may satisfy conditions of (1) and (2) below:
- the transcription factor may be Foxo3a.
- the obtained primordial follicle may further satisfy a condition of (3) below:
- FIG. 1 shows a to d which are immunostaining images of gonad sections of 3.5-day-old female mouse in Reference Example 1.
- a scale bar represents 10 ⁇ m.
- a is an immunostaining image using an antibody against Mouse Vasa homolog (MVH) of a germ cell marker.
- b is an immunostaining image using an antibody against fibronectin, which is an extracellular matrix.
- c is a staining image using Alexa Fluor 488-labeled phalloidin that specifically binds to F-actin which is a stress fiber.
- d is an image in which a nuclear-staining image using 4′,6-diamidino-2-phenylindole (DAPI) is superimposed on the staining images in a to c.
- DAPI 4′,6-diamidino-2-phenylindole
- a′ to d′ are magnified images of portions surrounded by squares in a to d, respectively.
- a scale bar represents 10 ⁇ m.
- e to h are immunostaining images of gonad sections of 12.5-day-old female mouse after fertilization in Reference Example 1.
- a scale bar represents 10 ⁇ m.
- e is an immunostaining image using an antibody against the MVH of a germ cell marker.
- f is an immunostaining image using an antibody against fibronectin, which is an extracellular matrix.
- g is an immunostaining image using an antibody against F-actin, which is a stress fiber.
- h is an image in which a nuclear-staining image using DAPI is superimposed on the immunostaining images in a to c.
- e′ to h′ which are magnified images of portions surrounded by squares in e to h, respectively.
- FIG. 2 shows a to c which are immunostaining images of gonad sections which were obtained by culturing gonads of 12.5 day-old female mouse after the fertilization under a pressurized condition and collecting the gonad sections on the 21st day from the start of the culturing in Example 1.
- a is an immunostaining image using an antibody against the MVH of a germ cell marker.
- b is an immunostaining image using an antibody against a transcription factor Foxo3a.
- c is an image in which a nuclear-staining image using DAPI is superimposed on the immunostaining images in a and b.
- a scale bar represents 10 ⁇ m.
- FIG. 3 shows captured images, taken by a fluorescent stereomicroscope, of gonad sections which were obtained by culturing gonads of 12.5 day-old female mouse after the fertilization under a steady condition (Control) or a pressurized condition (Pressured) and collecting the gonad sections on the 21st day from the start of the culturing in Example 1.
- Oocytes were visualized by fluorescence of a cyan fluorescent protein (CFP) expressed under a control of expression of Stella, which is an oocyte marker.
- a scale bar represents 50 ⁇ m.
- FIG. 4 A shows immunostaining images of immobilized gonads of 7.5 day-old female mouse obtained by performing phosphate saline (PBS), proteolytic enzyme treatment (CTK), and proteolytic enzyme treatment under a pressurized condition (CTK (P)) for one hour in Example 1.
- PBS phosphate saline
- CTK proteolytic enzyme treatment
- P pressurized condition
- a, e, and i are staining images for CFP expressed under the control of the expression of the germ cell marker Stella.
- b, f, and j are immunostaining images using an antibody against the transcription factor Foxo3a.
- c, g, and k are immunostaining images using an antibody against the MVH of the germ cell marker.
- d is an image in which a nuclear-staining image using DAPI is superimposed on the staining images in a to c.
- h is an image in which a nuclear-staining image using DAPI is superimposed on the staining images in e to g.
- l is an image in which a nuclear-staining image using DAPI is superimposed on the staining images in i to k.
- a scale bar represents 10 ⁇ m.
- FIG. 4 B is a graph showing a proportion of oocytes that localizes the transcription factor Foxo3a in the immobilized gonads of 7.5 day-old female mouse obtained by performing phosphate saline (PBS), proteolytic enzyme treatment (CTK), and proteolytic enzyme treatment under a pressurized condition (CTK (P)) for one hour in Example 1.
- PBS phosphate saline
- CTK proteolytic enzyme treatment
- P pressurized condition
- FIG. 5 shows a to c which are immunostaining images of gonad sections which were obtained by culturing gonads of 12.5 day-old female mouse after the fertilization under a low oxygen concentration condition and collecting the gonad sections on the 21st day from the start of the culturing in Example 2.
- a is an immunostaining image using an antibody against the MVH of a germ cell marker.
- b is an immunostaining image using an antibody against a transcription factor Foxo3a.
- c is an image in which a nuclear-staining image using DAPI is superimposed on the immunostaining images in a and b.
- a scale bar represents 10 ⁇ m.
- FIG. 6 A shows captured images, taken by a fluorescent stereomicroscope, of gonad sections which were obtained by culturing gonads of 12.5 day-old female mouse after fertilization, adding LY294002 (hereinafter, may be abbreviated as “Ly”) which is a PI3K inhibitor from the 6th day from the start of the culturing, and collecting the gonad sections on the 16th day from the start of the culturing in Reference Example 2.
- Upper drawings are bright field images
- middle drawings are fluorescence images
- lower drawings are enlarged images respectively of the middle drawings.
- the oocytes were visualized by the fluorescence of CFP expressed under the control of the expression of Stella, which is the oocyte marker.
- a scale bar represents 50 ⁇ m.
- FIG. 6 B is a graph showing a proportion of oocytes of each size calculated by counting the number of oocytes using the expression of Stella-CFP as an index using the fluorescence images shown in FIG. 6 A .
- FIG. 7 shows immunostaining images of gonad sections which were obtained by culturing gonads of 12.5 day-old female mouse after fertilization, adding Ly from 6th day from the start of the culturing, further culturing the gonads under the pressurized condition (Press (33.3 kPa)), and collecting the gonad sections on the 16th day from the start of the culturing in Example 3.
- a and e are staining images for CFP expressed under the control of the expression of the germ cell marker Stella.
- b and f are immunostaining images using an antibody against a transcription factor Foxo3a.
- c and g are immunostaining images using an antibody against the MVH of the germ cell marker.
- d is an image in which a nuclear-staining image using DAPI is superimposed on the staining images in a to c.
- h is an image in which a nuclear-staining image using DAPI is superimposed on the staining images in e to g.
- a scale bar represents 10 ⁇ m.
- FIG. 8 A is a graph showing a proportion of oocytes that localizes the transcription factor Foxo3a in a cell nucleus in the oocytes of 20 ⁇ m or smaller by analyzing the immunostaining images shown in b and f of FIG. 7 .
- FIG. 8 B is a graph showing a proportion of oocytes that localizes the transcription factor Foxo3a in a cytosol in the oocytes of 20 ⁇ m or smaller by analyzing the immunostaining images shown in b and f of FIG. 7 .
- FIG. 9 is a graph showing results of a flow cytometry analysis of gonad sections obtained by culturing 3.5-day-old ovaries and a gonad of 12.5-day-old female mouse after fertilization under each condition and collecting the gonad sections on the 21st day from the start of the culturing in Example 4.
- the upper row shows a two-dimensional histogram of forward scattered light (FSC) indicating a cell size and fluorescence of CFP expressed under the control of the germ cell marker Stella.
- the lower row shows a histogram showing a distribution of FSC in CFP-expressing cells.
- the “Merge” at the right end of the lower row shows a histogram in which four histograms in the lower row are superposed.
- FSC forward scattered light
- a method according to the present embodiment is a method of differentiating a primordial germ cell into a primordial follicle in vitro, the method including culturing a primordial germ cell and a supporting cell adjacent to the primordial germ cell under a pressurized condition or a low oxygen concentration condition.
- the culturing step may be referred to as a “step (A)” below.
- the formation of a primordial follicle was not confirmed, and functional oogenesis was transient.
- the primordial germ cell and the supporting cell adjacent to the primordial germ cell can be efficiently differentiated into a primordial follicle.
- the “follicle” referred to here includes an egg cell and a somatic cell (granulosa cell and capsule cell) surrounding the egg cell.
- the method of the present embodiment can be useful for elucidating the mechanism of maintenance and activation of oocytes.
- a “primordial germ cell” refers to a cell which is planned to differentiate into a germ cell, and finally differentiates into an egg or a sperm through meiosis.
- the primordial germ cell may be derived from a living body, or may be a primordial germ cell like cell (PGCLC) that has been induced to differentiate from a pluripotent stem cell.
- PPCLC primordial germ cell like cell
- the primordial germ cells can be collected together with a gonad from a female mouse fetus (from 11.5 to 12.5 days old).
- the gonads may be collected together with the mesonephros, or the mesonephros may be separated or collected.
- the “primordial germ cell” includes a primordial germ cell like cell differentiated from a pluripotent stem cell.
- the “pluripotent stem cell” refers to an undifferentiated cell having “self-renewal ability” capable of proliferating while maintaining an undifferentiated state and “differentiation pluripotency” capable of differentiating into all three germ layer lines.
- the pluripotent stem cell is not limited to the followings, and examples thereof include induced pluripotent stem cells (iPS cells), embryonic stem cells (ES cells), embryonic germ cells derived from primordial germ cells (EG cells), and testis tissue.
- Examples thereof include multipotent germline STEM cells (mGS cells) isolated in the process of establishing and culturing GS cells from, and Muse cells isolated from bone marrow mesenchymal cells.
- the ES cell may be an ES cell generated by nuclear reprogramming from a somatic cell.
- the pluripotent stem cells listed above can be obtained by known methods.
- iPS cell refers to a cell that can be reprogrammed into cells of various tissues and organs by introducing some genes into differentiated somatic cells.
- the iPS cells used for inducing differentiation of primordial germ cells may be derived from primary cultured cells of somatic cells collected from an appropriate donor, or may be derived from an established cell line. Since iPS cells can induce differentiation into any germ layer cells, the somatic cells used for preparing iPS cells may be, in principle, derived from either ectoderm or endoderm cells. Cells in skin, hair, gingiva, blood, or the like which are less invasive and easy to collect, and are suitable as somatic cells used for the preparation of iPS cells.
- a method known in the art may be followed. Specifically, for example, the preparation methods described in known references such as “Okita K. et al.,” Generation of germline-competent induced pluripotent stem cells. “, Nature, Vol. 448, p 313 -317, 2007.” (Reference 1), and “Hamanaka S. et al., “Generation of germline-competent rat induced pluripotent stem cells.”, PLoS One, Vol. 6, Issue 7, e22008, 2011.” (Reference 2) are available.
- ES cells used for inducing differentiation of primordial germ cells can be obtained by a known method. For example, it can be established by collecting an inner cell mass from the blastocyst of a fertilized egg of a target animal and culturing the inner cell mass on a feeder cell derived from fibroblasts. In addition, ES cells established by culturing an early embryo produced by nuclear transplantation of a nucleus of a somatic cell can also be used.
- a method of inducing differentiation of primordial germ cell like cells from iPS cells or ES cells can be performed by referring to a known method, for example, Hayashi K. et al., “Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells.”, Cell, Vol. 146, No. 4, p519-532, 2011.” (Reference 3) or the like.
- pluripotent stem cell-derived PGCLC is used as the primordial germ cell
- a method is known. For example, by introducing a nucleic acid encoding a fusion protein in which Blimp1, which is a marker gene of primordial germ cells, and a reporter protein are bound, to pluripotent stem cells, PGCLC induced to be differentiated from pluripotent stem cells and undifferentiated cells can be easily separated by a Fluorescence-activated cell sorting (FACS) method or the like.
- FACS Fluorescence-activated cell sorting
- primordial germ cells in the present specification are primordial germ cells derived from living body and primordial germ cell like cells derived from pluripotent stem cells listed above, and also includes cells in which the gene of the cell is modified by using a genetic engineering technique.
- TALEN Transcription Activator-Like Effector Nucleases
- TALEN Transcription Activator-Like Effector Nucleases
- zinc finger nuclease zinc finger nuclease
- homologous recombination method it is possible to introduce the target nucleic acid, vector, or the like.
- the method of introducing a nucleic acid, a vector, or the like include a microinjection method (microinjection), an electroporation method, a lipofection method, and a nucleic acid introduction method using a viral vector.
- the method of introducing a foreign gene or a foreign nucleic acid fragment is not limited to the methods listed above as long as the genetically modified primordial germ cell can be differentiated into a functional oocyte by the method of the present embodiment.
- the gene modification to the primordial germ cell can be performed at an appropriate timing during the culture period of the primordial germ cell. For example, in a mouse, the gene modification can be performed during the period from 11.5 to 12.5 days old. Also, in a case where primordial germ cell like cells derived from pluripotent stem cells are used, the pluripotent stem cells before the induction of differentiation into primordial germ cell like cells can be genetically modified by a known method.
- the “supporting cell” refers to cells surrounding a primordial germ cell, and in a sexually differentiated ovary, cells that differentiate into granulosa cells or capsule cells.
- the supporting cells will be used for co-culture of primordial germ cells in the future because the supporting cells will differentiate into granulosa cells and capsule cells that make up follicles. Therefore, it is preferable to culture the primordial germ cells in a manner that a gonad is cultured as it is, or co-cultured so that the primordial germ cell and the supporting cell are in contact with each other.
- pluripotent stem cell-derived PGCLC is used as a primordial germ cell, somatic cells derived from the gonad collected from a living body can be used as a supporting cell.
- somatic cells derived from the gonad collected from a living body as supporting cells
- the method of collecting somatic cells derived from the gonad and the method of producing an aggregate including pluripotent stem cell-derived PGCLC and somatic cells derived from the gonad can be performed according to the method described in Reference 3.
- the gonad in the method of collecting somatic cells derived from the gonad, can be surgically collected from a living body, and the somatic cells configuring the gonad can be dissected by trypsin treatment or the like.
- the method of removing the germ cells in the gonad can be carried out by a known method.
- the inherent germ cells can be removed by a Magnetic activated cell sorting method using an anti-SSEA1 antibody or an anti-CD31 antibody.
- the gonad for collecting the somatic cells as supporting cells are preferably derived from the fetus.
- a gonad derived from a mouse fetus with a fetal age of 12.5 days can be used.
- a person skilled in the art can appropriately select the gonad at a preferable time depending on the animal species from which the gonad is derived, based on the present disclosure and common general knowledge in the art.
- a method of producing an aggregate including pluripotent stem cell-derived PGCLC and somatic cells derived from the gonad can be carried out by, for example, mixing, aggregating, and culturing pluripotent stem cell-derived PGCLC and somatic cells derived from the gonad in a GK15 medium containing Retinoic Acid (a medium obtained by adding 15% KSR in GMEM (KnockOut (registered trademark) Serum Replacement), 1 ⁇ GlutaMax (registered trademark), 1 ⁇ penicillin/streptomycin (100 U/mL Penicillin and 0.1 mg/mL streptomycin), 100 ⁇ M 2-mercaptoethanol (2ME), and 1 ⁇ M Reproductive Acid to GMEM). It is preferable to use a culture dish with low adsorption for culturing.
- Retinoic Acid a medium obtained by adding 15% KSR in GMEM (KnockOut (registered trademark) Serum Replacement), 1 ⁇ GlutaMax (registered trademark),
- the culture period for producing aggregates can be approximately 2 days or more and 3 days or less, preferably 2 days. Further, those skilled in the art can appropriately set a preferable culture period depending on the animal species from which the cells are derived.
- the ratio of pluripotent stem cell-derived PGCLC to somatic cells derived from the gonad is not limited as long as the produced aggregates form primordial follicles, and in the case of the mouse, for example, the ratio of the number of pluripotent stem cell-derived PGCLCs to the somatic cells derived from the gonad is preferably set to about 1:10.
- the primordial germ cells and supporting cells, or the gonad containing the primordial germ cells and supporting cells those that have been cryopreserved can also be used.
- the cryopreservation method can be carried out by a known method.
- cryopreservation of primordial germ cells and supporting cells can be performed by a slow freezing method using a 10% DMSO solution or a commercially available freezing agent (such as Celbanker (registered trademark)).
- primordial germ cells used in the method of the present embodiment those derived from mammals are used.
- mammals include humans, chimpanzees and other primates; livestock animals such as dogs, cats, rabbits, horses, sheep, goats, cows, pigs, rats (including nude rats), mice (including nude and skid mice), hamsters, guinea pigs; pet animals; and experimental animals, but are not limited thereto.
- step (A) a primordial germ cell and a supporting cell adjacent to the primordial germ cell are cultured under a pressurized condition or a low oxygen concentration condition to form primordial follicle. Also, in a case where the gonad collected from the living body is used in the step (A), it is not necessary to isolate the primordial germ cell and the supporting cell from the gonad, and it is possible to culture the gonad as it is or as aggregates of the isolated primordial germ cell and the supporting cells or as a several tissue sections.
- the expression “culture of primordial germ cells and supporting cells adjacent to the primordial germ cells” in the step (A) includes a case of culturing gonad containing the primordial germ cell and the supporting cell, aggregates of the isolated primordial germ cells and the supporting cells, or a portion thereof.
- the primordial germ cells and the supporting cells can be isolated from the gonad and cultured.
- a condition in which a culture solution containing the primordial germ cell or the supporting cell or containing a gonad containing the primordial germ cell and the supporting cell is applied with a hydrostatic pressure of higher than 23 kPa and 40 kPa or lower is preferable, a condition in which the hydrostatic pressure of 28 kPa or higher and 38 kPa or lower is applied is more preferable, a condition in which the hydrostatic pressure of 30 kPa or higher and 35 kPa or lower is applied is still more preferable, and a condition in which the hydrostatic pressure of 32 kPa or higher and 34 kPa or lower is applied is particularly preferable.
- the primordial germ cells can be more efficiently differentiated into primordial follicles.
- pressurization method for example, as described in Examples to be described later, a method using a commercially available pressurization culture device such as AGP-3001S (registered trademark) of STREX can be mentioned.
- the low oxygen concentration condition regarding the oxygen concentration in the culture atmosphere, a condition of 7% or lower is preferable, a condition of 3% or higher and 7% or lower is more preferable, and a condition of 4% or higher and 6% or lower is still more preferable, and a condition of 5% is particularly preferable.
- the primordial germ cells can be more efficiently differentiated into primordial follicles.
- a culture method under the low oxygen concentration condition for example, as described in Examples to be described later, a culture method using a commercially available incubator capable of adjusting the oxygen concentration such as APM30D manufactured by Astec Co., Ltd. can be mentioned.
- the conditions may be started at the start time of culturing the primordial germ cell and the supporting cell adjacent to the primordial germ cell, and may be started in the middle of culturing according to the time when the formation of the primordial follicle is started.
- the culture temperature can be, for example, 25° C. or higher and 40° C. or lower, and for example, 30° C. or higher and 37° C. or lower.
- the culture period for forming atomic follicles from primordial germ cells varies depending on the animal species from which the primordial germ cells to be cultured are derived, but it is preferable that the period until the primordial germ cells form atomic follicles in vivo is used as a guide. In a case of culturing the mouse primordial germ cells, it is preferable to culture the mouse primordial germ cells for a number of days corresponding to around 10 days after birth.
- the culture period is preferably 14 days or more and 21 days or less, more preferably 16 days or more and 21 days or less, and still more preferably 18 days or more and 21 days or less.
- the number of days is 11 days or more and 21 days or less counting from the start of culturing the aggregates prepared in advance.
- a known basal medium can be used, and examples thereof include ⁇ -MEM, PRMI1640, 199, and StemPro (registered trademark)-34 SFM, and these basal media can be used by adding serum or alternative serum thereto.
- the basal medium used in the step (A) is not limited to those listed above as long as the primordial germ cells differentiate into primordial follicles.
- the basal medium may appropriately contain other components such as ascorbic acid and penicillin as long as other components do not interfere with the differentiation of primordial germ cells into primordial follicles.
- ⁇ -MEM can be used as the basal medium for the first half culture for forming primordial follicles from primordial germ cells
- StemPro (registered trademark)-34 SFM can be used as the basal medium for the second half culture.
- the formation of primordial follicles from primordial germ cells can be achieved by using one basal medium, but by changing the basal medium used, the proliferation of granulosa cells can be further promoted, and the follicle structure is less likely to be broken when the formed primordial follicles is isolated, which is preferable.
- Such an effect of further promoting the proliferation of granulosa cells is particularly desirable in a case where primordial follicles are formed from cell aggregates of pluripotent stem cell-derived PGCLC and the somatic cells derived from the gonad.
- the medium can be replaced from the ⁇ -MEM to the StemPro (registered trademark)-34 SFM from the 4th day to the 8th day after the start of culturing the aggregates, and the 4th day after the start of the culture is more preferable.
- the medium can be replaced at the same time.
- the culture temperature, the culture period and the medium to be used have been exemplified, but those skilled in the art can appropriately set a preferable culture temperature, the culture period and the type of medium to be used, depending on the animal species from which the cells are derived.
- the culture of primordial germ cells in the step (A) is preferably carried out using a known insert membrane such as a Transwell-COL membrane in a culture dish such as a 6-well plate.
- a known insert membrane such as a Transwell-COL membrane in a culture dish such as a 6-well plate.
- Those skilled in the art can appropriately design and carry out the culture dish, insert membrane, timing of medium replacement, and the like, depending on the animal species from which the primordial germ cells to be cultured are derived.
- the step (A) may be carried out under the pressurized condition and the low oxygen concentration condition. Accordingly, the primordial germ cells can be more efficiently differentiated into primordial follicles.
- the proportion of oocytes having a smaller size is larger than that in a case of performing the culture under pressurized condition or low oxygen concentration condition.
- the step (A) may be carried out under the pressurized condition or low oxygen concentration condition, and further in the presence of a PI3 kinase inhibitor.
- PI3 kinase phosphatidylinositol-3 kinase
- PI3K phosphatidylinositol-3 kinase
- Mammals are classified into four subclasses: Class IA, Class IB, Class II, and Class III.
- activation of PI3K signals promotes maturation of oocytes (Reference 4: “Li J et al., “Activation of dormant ovarian follicles to generate mature eggs.”, PNAS., Vol. 107, No. 22, p10280-10284, 2010.”).
- the inventors found that the primordial germ cells can be more efficiently differentiated into primordial follicles by performing a combination of the pressurized condition and addition of the PI3 kinase inhibitor, as shown in Examples to be described later.
- Examples of the PI3K inhibitor include those that inhibit the function of PI3K.
- Specific examples of the PI3K inhibitor include low molecular weight compounds, PI3K expression inhibitors, and PI3K-specific binding substances.
- Examples of low molecular weight compounds as the PI3K inhibitor include Pictilisib (GDC-0941) (CAS No. 957054-30-7), LY294002 (CAS No. 154447-36-6), Idelalisib (CAL-101, GS-1101) (CAS No. 870281-82-6), Buparlisib (BKM120, NVP-BKM120) (CAS No. 944396-07-0), PI-103 (CAS No. 371935-74-9), TGX-221 (CAS No. 663619-89-4), IC-87114 (CAS No. 371242-69-2), and Wortmannin (CAS No. 19545-26-7), but are not limited thereto.
- PI3K expression inhibitor examples include siRNA, shRNA, miRNA, ribozyme, antisense nucleic acid, and low molecular weight compounds.
- a small interfering RNA is a small double-stranded RNA of 21 base pairs or more and 23 base pairs or less used for gene silencing by RNA interference.
- the siRNA introduced into the cell binds to RNA-induced silencing complex (RISC). This complex binds to and cleaves mRNA with a sequence complementary to siRNA. As a result, gene expression is suppressed in a sequence-specific manner.
- RISC RNA-induced silencing complex
- the siRNA can be prepared by synthesizing the sense strand and antisense strand oligonucleotides with a DNA/RNA automatic synthesizer, respectively, for example, denaturing in an appropriate annealing buffer at about 90° C. or higher and 95° C. or lower for about 1 minute, and then annealing at about 30° C. or higher and 70° C. or lower for about 1 hour or more and 8 hours or less.
- SiRNAs, shRNAs, miRNAs, ribozymes and antisense nucleic acids may contain various chemical modifications to improve stability and activity.
- a phosphate residue may be replaced with a chemically modified phosphate residue such as phosphorothioate (PS), methylphosphonate, or phosphorodithionate.
- PS phosphorothioate
- methylphosphonate methylphosphonate
- phosphorodithionate phosphorodithionate
- at least a part thereof may be configured of nucleic acid analogs such as peptide nucleic acid (PNA).
- PNA peptide nucleic acid
- Examples of the PI3K-specific binding substance include those that specifically bind to PI3K and inhibit the function of PI3K, and examples thereof include antibodies, antibody fragments, and aptamers.
- the antibody can be produced, for example, by immunizing an animal such as a mouse with the PI3K protein or a fragment thereof as an antigen. Alternatively, the antibody can be prepared, for example, by screening a phage library. Examples of the antibody fragment include Fv, Fab, and scFv.
- the above antibody is preferably a monoclonal antibody. Moreover, a commercially available antibody may be used.
- the aptamer is a substance having a specific binding ability to a target substance.
- examples of the aptamer include nucleic acid aptamers and peptide aptamers.
- Nucleic acid aptamers having a specific binding ability to a target peptide can be selected, for example, by a systematic evolution of ligand by exponential enrichment (SELEX) method or the like.
- the peptide aptamer having a specific binding ability to the target peptide can be selected by, for example, a Two-hybrid method using yeast.
- the amount of the PI3K inhibitor added can be appropriately selected depending on the type of inhibitor to be used.
- the final concentration in the medium can be set to about 0.01 ⁇ M or higher and 300 ⁇ M or lower, and can be set to about 0.1 ⁇ M or higher and 100 ⁇ M or lower.
- the amount of the PI3K inhibitor added is within the above range, the maturation of oocytes can be suppressed more effectively.
- the conditions may be started at the start time of culturing the primordial germ cell and the supporting cell adjacent to the primordial germ cell, and may be started in the middle of culturing according to the time when the formation of the primordial follicle is started.
- the step (A) is carried out under the pressurized condition or the low oxygen concentration condition, and further under a condition in which an influence of estrogen or a factor having a function similar to a function of the estrogen is eliminated.
- estrone refers to a kind of sex steroid hormone, which is generated by metabolism from androgen in the granulosa cells of the ovary. The released estrogen activates transcription of a specific gene by binding to the estrogen receptor.
- Estrone Three types of estrogen are known, estrone (E1), estradiol (E2), and estriol (E3), and these are included when referred to as estrogen in the present specification.
- the “sex steroid hormone” includes androsterone such as testosterone, dehydrotestosterone, androsterone in addition to the estrogen.
- expression refers to that the factor has the same function as or a function similar to that of estrogen or sex steroid hormone.
- the term “function similar to estrogen” or a “function similar to sex steroid hormone” refers to the following (i) or (ii) when primordial germ cells are cultured in vitro.
- the factor having a function similar to the function of estrogen or sex steroid hormone examples include factors that bind to sex steroid hormone receptors such as estrogen and androgen, and specifically, phenol red in a medium.
- serum may contain factors that have a function similar to the function of unidentified estrogen, in some cases. Therefore, it is preferable that such estrogen or sex steroid hormones may be contained.
- the culture conditions are such that the influence of a factor having a function similar to the function of estrogen or sex steroid hormone can be eliminated.
- oocyte cyst refers to a state in which cells are connected by an intercellular bridge due to incomplete cytokinesis during the embryonic period.
- culture in the presence of “sex steroid hormone inhibitor” is included.
- one example thereof includes culturing in the presence of an “estrogen inhibitor”.
- the “sex steroid hormone inhibitor” includes not only an estrogen inhibitor and an androgen inhibitor, but also a combination of the androgen inhibitor and the estrogen inhibitor.
- the “estrogen inhibitor” or “sex steroid hormone inhibitor” used in the method of the present embodiment has an action capable of inhibiting the activation of an estrogen receptor or a sex steroid hormone receptor.
- the inhibitor include an antagonist of estrogen receptor, ICI 182,780 ((7R, 9S, 13S, 14S, 17S)-7-(9-(4,4,5,5,5-Pentafluoropentylsulfinyl)nonyl))-7,8,9,11,12,13,14,15,16,17-decahydro-13-methyl-6H-cyclopenta[a]phenanthrene-3,17-diol).
- ICI 182,780 ((7R, 9S, 13S, 14S, 17S)-7-(9-(4,4,5,5,5-Pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-13-methyl-6H-cyclopenta[a]phenanthrene-3,17-diol).
- sex steroid hormone inhibitors as an inhibitor of androgen receptor, commercially available products such as KW-365 (N-[4-[(Benzyl)(4-nitrophenyl) amino]-1-methylpyrrole-2-carbonyl]pyrrolidine) can be used.
- the estrogen and sex steroid hormone inhibitors are not limited to those described above, and as long as the inhibitors have an action capable of inhibiting the activation of estrogen and sex steroid hormone receptors and can differentiate primordial germ cells into primordial follicles, the inhibitors can be used.
- Inhibition of activation of estrogen and sex steroid hormone receptors by addition of estrogen and sex steroid hormone inhibitors is considered to be able to control at least one of oocyte cyst disruption and primordial follicle formation. Therefore, it is preferable that the estrogen inhibitor is added at a timing prior to the timing at which at least one of oocyte cyst disruption and primordial follicle formation occurs.
- the primordial germ cells and the supporting cells adjacent to the primordial germ cells “under the condition in which the influence of sex steroid hormones (for example, an influence of estrogen or a factor having a function similar to the estrogen) is eliminated” from the start of culturing, and it is preferable to perform the culture “under the condition in which the influence of sex steroid hormones (for example, influence of the estrogen or a factor having a function similar to a function of the estrogen) is eliminated” at least when at least one of oocyte cyst disruption and primordial follicle formation occurs.
- sex steroid hormones for example, an influence of estrogen or a factor having a function similar to the estrogen
- an estrogen inhibitor is used as a sex steroid hormone inhibitor and a mouse is used as an animal species
- a mouse disruption in many oocyte cysts occurs from 17.5 days before and after birth. Therefore, it is preferable to add the estrogen inhibitor from the number of days of culture corresponding to the time of such fetal age.
- the gonads are collected at a fetal age of 12.5 days and the culture of primordial germ cells is started from the collection day, the 5th day of in vitro culture is considered to correspond to the 17.5th day of fetal age.
- the culture period in a medium containing an estrogen inhibitor is preferably a period during which the disruption of oocyte cysts and the formation of primordial follicles are completed.
- the culture period is 6 days from the 5th day of the culture to the 11th day of the culture.
- the culture period is 4 days from the 7th day to the 10th day of the culture, counting from the start of the culture of the aggregates prepared in advance.
- the culture period of the “estrogen inhibitor”, as appropriate is the period of culturing under “condition in which the influence of sex steroid hormones (for example, the influence of estrogen or a factor having a function similar to a function of the estrogen) is eliminated” is the period during which the disruption of oocyte cysts and the formation of primordial follicles are completed.
- the culture under the above condition may begin after the oocyte cysts begin to disintegrate, and may be stopped before the formation of primordial follicles is complete, as long as functional oocytes are obtained.
- the estrogen inhibitor and the sex steroid hormone inhibitor can be used by adding these inhibitors to a known basal medium used for culturing primordial germ cells.
- a basal medium include those similar to the basal medium exemplified above.
- ICI 182,780 When, for example, ICI 182,780 is used as the estrogen inhibitor when culturing mouse primordial germ cells, it is preferable to add the ICI 182,780 to the medium within a range of 0.01 ⁇ M or higher and 50 ⁇ M or lower (final concentration), and more preferably within a range of 0.1 ⁇ M or higher and 10 ⁇ M or lower (final concentration).
- the basal medium For culturing during the period in which the estrogen inhibitor is not added, the basal medium exemplified above may be used for culturing.
- the serum-free medium may be a known serum-free medium (for example, a serum-free medium prepared so that it can be used as it is, such as StemPro (registered trademark)-34 SFM), or a serum-free medium prepared by using an alternative serum.
- the serum-free medium can be prepared by adding, to the basal medium, a commercially available alternative serum such as Serum Protein Substitute (SPS), KSR, serum substitute supplement (SSS) (registered trademark), instead of fetal bovine serum (FBS).
- SPS Serum Protein Substitute
- KSR serum substitute supplement
- FBS fetal bovine serum
- SPS or KSR is preferable.
- basal medium to be used in the preparation of the serum-free medium examples include those similar to the basal medium exemplified above.
- the basal medium used in the step (A) is not limited to those listed above as long as the primordial germ cells differentiate into primordial follicles.
- the SPS instead of a serum such as FBS is used as a culture condition in which the influence of sex steroid hormones (for example, the influence of estrogen or a factor having a function similar to a function of the estrogen) is eliminated
- the medium in a range of 5% or higher and 20% or lower (final concentration), and more preferably 10% (final concentration).
- concentration of the alternative serum depending on the animal species from which the primordial germ cells are derived, the basal medium to be used, the alternative serum to be used, and the like.
- the period for culturing using the serum-free medium is preferably a period during which the disruption of oocyte cysts and the formation of primordial follicles are completed. It is also possible to perform culture by using the serum-free medium from beginning to end during the culture period of the primordial germ cells in the step (A).
- Those skilled in the art can appropriately adjust the timing of switching from the serum medium to the serum-free medium, as appropriate, depending on the animal species from which the primordial germ cells are derived or the serum-free medium to be used.
- a serum-free medium it is preferable to perform the culture using a medium in which a serum such as FBS is added to the basal medium listed above, but as described above, it is possible to perform the culture in a serum-free medium from beginning to end, during culturing of the gonads.
- the basal medium may appropriately contain other components such as ascorbic acid and penicillin as long as other components do not interfere with the differentiation of primordial germ cells into primordial follicles.
- the primordial follicle obtained by using the method of the present embodiment satisfies the following conditions of (1) and (2):
- the follicle is closer to the atomic follicle formed in the living body.
- Examples of the transcription factor having a function of maintaining follicle maturation in the resting phase include Foxo3a (also referred to as Fkhr2, C76856, FKHRL1, 1110048B16Rik, and 2010203A17Rik).
- the primordial follicle obtained by using the method of the present embodiment satisfies, in addition to the conditions of (1) and (2), the following condition of (3):
- the conditions of (1) and (3) above can be evaluated visually using, for example, a microscope. Also, the condition of (1) above can be evaluated by immunostaining using an antibody against a protein (for example, fibronectin) expressed by granulosa cells.
- a protein for example, fibronectin
- the condition of (2) can be evaluated by, for example, immunostaining using an antibody (for example, an anti-Foxo3a antibody) against the transcription factor.
- an antibody for example, an anti-Foxo3a antibody
- a commercially available nuclear staining reagent for example, 4′,6-diamidino-2-phenylindole (DAPI)
- DAPI 4′,6-diamidino-2-phenylindole
- the primordial follicles obtained by using the method of the present embodiment are suitably used for infertility treatment. That is, in one embodiment, the present invention provides a method of treating an infertility using the primordial follicle obtained by the above method.
- the primordial follicles obtained by using the method of the present embodiment are suitably used for efficient breeding of industrial animals and breeding of rare animals. That is, in one embodiment, the present invention provides a method of breeding industrial animals or a method of breeding rare animals using the primordial follicles obtained by the above method.
- Mammals are preferable as the target animals. Mammals include those similar to those provided as exemplary examples above.
- primordial follicles obtained by using the method of the present embodiment can be useful for investigating the cause of infertility and elucidating the mechanism of menopausal diseases.
- a gonad was excised from each of female mouse 3.5 day-old and a fetus of a female mouse (12.5 days after fertilization) and a frozen section was prepared. Specifically, the gonad was immersed in PBS containing 4% paraformaldehyde and immobilized at 4° C. for 3 hours. Then, the gonad was treated stepwise with 10%, 15%, and 20% sucrose, and was embedded in an O.C.T. compound (manufactured by Tissue-Tek) and frozen. Next, a section having a thickness of 7 ⁇ m was prepared from the frozen gonad.
- a tissue section of the gonad obtained in (1) was immersed in a solution containing a 200-fold diluted mouse anti-Ddx4/MVH polyclonal antibody (manufactured by Abcam Plc.) and a 500-fold diluted rabbit anti-fibronectin antibody (manufactured by Sigma), and then subjected to a primary antibody-antigen reaction at 4° C. overnight.
- a 200-fold diluted mouse anti-Ddx4/MVH polyclonal antibody manufactured by Abcam Plc.
- a 500-fold diluted rabbit anti-fibronectin antibody manufactured by Sigma
- the tissue section of the gonad was immersed in solutions respectively containing a 500-fold diluted Alexa Fluor 647-labeled anti-mouse IgG antibody (Molecular robes, manufactured by Life Technologies) and a 500-fold diluted Alexa Fluor Plus 555-labeled anti-rabbit IgG antibody, and subjected to a secondary antibody-antigen reaction at a room temperature for 3 hours.
- the tissue section of the gonad was immersed in a solution containing a 1000-fold diluted Alexa Fluor 488-labeled Phalloidin and subjected to a reaction at a room temperature for 1 hour.
- the tissue section of the gonad was stained with 4′,6-diamidino-2-phenylindole (DAPI) (manufactured by Wako Pure Chemical Industries, Ltd.).
- DAPI 4′,6-diamidino-2-phenylindole
- FIG. 1 The tissue section of the gonad immunostained in (2) was observed with a confocal microscope (model number: Zeiss LSM 700, manufactured by Carl Zeiss). Results are shown in FIG. 1 .
- a to d are immunostaining images of gonad sections of 3.5-day-old female mouse.
- a scale bar represents 10 ⁇ m.
- a is an immunostaining image using an antibody against the MVH of a germ cell marker.
- b is an immunostaining image using an antibody against fibronectin, which is an extracellular matrix.
- c is an immunostaining image using an antibody against F-actin, which is a stress fiber.
- d is an image in which a nuclear-staining image using DAPI is superimposed on the immunostaining images in a to c.
- a′ to d′ are magnified images of portions surrounded by squares in a to d, respectively.
- a scale bar represents 10 ⁇ m.
- e to h are immunostaining images of gonad sections of 12.5-day-old female mouse after fertilization.
- a scale bar represents 10 ⁇ m.
- e is an immunostaining image using an antibody against the MVH of a germ cell marker.
- f is an immunostaining image using an antibody against fibronectin, which is an extracellular matrix.
- g is an immunostaining image using an antibody against F-actin, which is a stress fiber.
- h is an image in which a nuclear-staining image using DAPI is superimposed on the immunostaining images in a to c.
- e′ to h′ which are magnified images of portions surrounded by squares in e to h, respectively.
- a medium As a medium used for in vitro culture, a medium (hereinafter, this medium may be referred to as an “ ⁇ M2”) in which ⁇ MEM was used as a basal medium and 2% fetal bovine serum (FBS), 55 ⁇ M of 2-mercaptoethanol (2ME) (Gibco, Life Technologies), 1 ⁇ penicillin/streptomycin (Gibco, Life Technologies), and 1 ⁇ GlutaMax (registered trademark) (Gibco, Life Technologies) were added to the ⁇ MEM and a medium (hereinafter, this medium may be referred to as an “S10”) in which StemPro (registered trademark) (Gibco, Life Technologies) was used as a basal medium and 10% FBS, 55 ⁇ M of 2ME (Gibco, Life Technologies), 1 ⁇ penicillin/streptomycin (Gibco, Life Technologies), and 1 ⁇ GlutaMax (registered trademark) (Gibco, Life Technologies) were added to the StemPro were
- the gonad used for culturing was collected from a female mouse fetus (12.5 days after fertilization) or 7.5 day-old female mouse without mesonephros.
- Transwell-COL membrane (3.0 ⁇ m pore size, 24 mm diameter) (manufactured by Corning Inc.) was set in each well of a 6-well plate, and the gonad collected in (1) were placed on a membrane. Then, 1.3 mL of medium was added to each well and culture was performed for 21 days.
- AGP-3001S (registered trademark) manufactured by STREX was used to apply a hydrostatic pressure of 33.33 kPa. Also, the medium was cultured in ⁇ M2 for 4 days and then cultured in S10.
- ICI 182,780 (7 ⁇ ,17 ⁇ -[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol) (manufactured by Tocris Bioscience) which is an estrogen receptor antagonist was added during the period from 5th to 9th day after the start of culture such that a final concentration in the medium is 500 nM. About half of the medium was replaced with anew medium every other day. In addition, as a control, those cultured in the same manner without pressurization (cultured under a steady condition) were also prepared.
- a tissue section of the gonad was prepared by using the same method as in (1) of Reference Example 1.
- tissue section of the gonad obtained in (3) was immersed in solutions respectively containing a 200-fold diluted mouse anti-Ddx4/MVH polyclonal antibody (manufactured by Abcam) and a 200-fold diluted rabbit anti-Foxo3a polyclonal antibody (manufactured by Cell Signaling Technologies) and was subjected to a primary antibody-antigen reaction at 4° C. overnight.
- a 200-fold diluted mouse anti-Ddx4/MVH polyclonal antibody manufactured by Abcam
- a 200-fold diluted rabbit anti-Foxo3a polyclonal antibody manufactured by Cell Signaling Technologies
- the tissue section of the gonad was immersed in solutions respectively containing a 500-fold diluted Alexa Fluor 647-labeled anti-mouse IgG antibody (Molecular robes, manufactured by Life Technologies) and a 500-fold diluted Alexa Fluor Plus 555-labeled anti-rabbit IgG antibody (molecular robes, manufactured by Life Technologies), and subjected to a secondary antibody-antigen reaction at a room temperature for 3 hours.
- DAPI 4′,6-diamidino-2-phenylindole
- FIG. 2 shows typical results of the gonad cultured under the pressurized condition.
- a to c are immunostaining images of gonad sections which were obtained by culturing gonads of 12.5 day-old female mice after the fertilization under a pressurized condition and collecting the gonad sections on the 21st day from the start of the culturing. The magnification is 63 times.
- a is an immunostaining image using an antibody against the MVH of a germ cell marker.
- b is an immunostaining image using an antibody against a transcription factor Foxo3a.
- c is an image in which a nuclear-staining image using DAPI is superimposed on the immunostaining images in a and b.
- a scale bar represents 10 ⁇ m.
- FIG. 3 shows captured images taken by a fluorescent stereomicroscope (manufactured by Olympus Corporation, model number: SZX16) before producing a section of the gonad cultured in (2).
- “Control” is a gonad cultured under the steady condition
- “Pressured” is a gonad cultured under the pressurized condition.
- a scale bar represents 50 ⁇ m.
- a tissue section of this small follicle was prepared and examined in detail by immunostaining. As a result, it was confirmed that the section was surrounded by more flat granulosa cells and the transcription factor Foxo3a was localized in the nucleus of an egg (see a to c in FIG. 2 ).
- a gonad of 7.5-day-old female mouse was cultured for 1 hour by adding 0.5 mL of PBS (containing CTK) to each well of a 6-well plate.
- a composition of the CTK is 1 ⁇ M CaCl 2 ), 0.1 mg/mL Collagenase IV, 20% KSR (Invitrogen), and 0.025% Trypsin EDTA (Invitrogen).
- AGP-3001S registered trademark manufactured by STREX was used to apply a hydrostatic pressure of 33.33 kPa.
- a gonad cultured in PBS without containing CTK for 1 hour without performing the artificial pressurization and a gonad cultured in PBS containing CTK for 1 hour without performing the artificial pressurization were prepared.
- a tissue section of the gonad was prepared by using the same method as in (1) of Reference Example 1.
- FIG. 4 A The tissue section of the gonad immunostained in (6-3) was observed with a confocal microscope (model number: Zeiss LSM 700, manufactured by Carl Zeiss). The results are shown in FIG. 4 A .
- PBS is a gonad cultured in PBS without containing CTK for 1 hour without performing the artificial pressurization.
- CTK is a gonad cultured in PBS containing CTK for 1 hour without performing the artificial pressurization.
- CTK (P) is a gonad cultured in PBS containing CTK for 1 hour under the artificial pressurized condition.
- a, e, and i are staining images for CFP expressed under the control of the expression of the germ cell marker Stella.
- b, f, and j are immunostaining images using an antibody against the transcription factor Foxo3a.
- c, g, and k are immunostaining images using an antibody against the MVH of the germ cell marker.
- d is an image in which a nuclear-staining image using DAPI is superimposed on the staining images in a to c.
- h is an image in which a nuclear-staining image using DAPI is superimposed on the staining images in e to g.
- 1 is an image in which a nuclear-staining image using DAPI is superimposed on the staining images in i to k.
- a scale bar represents 10 ⁇ m.
- FIG. 4 B is a graph obtained by calculating a proportion of oocytes in which the transcription factor Foxo3a is localized in the nucleus, from the immunostaining image using the antibody against the transcription factor Foxo3a in FIG. 4 A .
- FIGS. 4 A and 4 B it was revealed that digestion of extracellular matrix by treating the gonad of 7.5-day-old female mouse with proteolytic enzymes (CTK) causes the Foxo3a of a primordial follicle egg to translocate to an outside of the nucleus and follicle maturation to be induced. Furthermore, it was revealed that this extranuclear translocation of the Foxo3a can be suppressed by performing the same proteolytic enzyme treatment under the artificially pressurized condition.
- CTK proteolytic enzymes
- the gonad and a medium were prepared using the same method as in (1) of Example 1.
- the gonad were in vitro cultured using the same method as in (2) of Example 1 except that the gonad was cultured under a low oxygen concentration condition instead of the artificially pressurized condition.
- culturing was performed under a 5% oxygen concentration condition using APM30D manufactured by Astec. As a control, those cultured in the same manner without the low oxygen concentration condition were also prepared.
- a tissue section of the gonad was prepared by using the same method as in (1) of Reference Example 1.
- FIG. 5 shows typical results of the gonad cultured under the low oxygen concentration condition.
- a to c are immunostaining images of gonad sections which were obtained by culturing gonads of 12.5 day-old female mice after the fertilization under the low oxygen concentration condition and collecting the gonad sections on the 21st day from the start of the culturing. The magnification is 63 times.
- a is an immunostaining image using an antibody against the MVH of a germ cell marker.
- b is an immunostaining image using an antibody against a transcription factor Foxo3a.
- c is an image in which a nuclear-staining image using DAPI is superimposed on the immunostaining images in a and b.
- a scale bar represents 10 ⁇ m.
- the gonad and a medium were prepared using the same method as in (1) of Example 1.
- Transwell-COL membrane (3.0 ⁇ m pore size, 24 mm diameter) (manufactured by Corning Inc.) was set in each well of a 6-well plate, and the gonad collected in (1) were placed on a membrane. Then, 1.3 mL of medium was added to each well and culture was performed for 16 days. Also, the medium was cultured in ⁇ M2 for 4 days and then cultured in S10.
- PI3K inhibitor LY294002 (hereinafter, may be abbreviated as “Ly”) (manufactured by Cell Signaling Technology, model number: 9901) was added to the medium such that a final concentration is 25 ⁇ M, during the period from the 6th day to the 16th day from the start of the culture.
- ICI 182,780 (7 ⁇ ,17 ⁇ -[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol) (manufactured by Tocris Bioscience) which is an estrogen receptor antagonist was added during the period from 5th to 9th day after the start of culture such that a final concentration in the medium is 500 nM. About half of the medium was replaced with a new medium every other day. In addition, as a control, those cultured in the same manner without adding Ly (cultured under a steady condition) were also prepared.
- FIG. 6 A The results are shown in FIG. 6 A .
- “Control” is a gonad cultured under a steady condition (in the absence of Ly)
- “Ly” is a gonad cultured in the presence of the PI3K inhibitor LY294002.
- a scale bar represents 50 ⁇ m.
- FIG. 6 B is a graph in which the number of oocytes was counted using the expression of Stella-CFP as an index in FIG. 6 A , and proportions of the oocytes smaller than 20 ⁇ m, 20 ⁇ m or larger and 50 ⁇ m or smaller, and larger than 50 ⁇ m were calculated.
- the gonad and a medium were prepared using the same method as in (1) of Example 1.
- gonad collected from 12.5 day-old female mouse was cultured under an artificially pressurized condition and in the presence of the PI3K inhibitor.
- Transwell-COL membrane (3.0 ⁇ m pore size, 24 mm diameter) (manufactured by Corning Inc.) was set in each well of a 6-well plate, and the gonad collected in (1) were placed on a membrane. Then, 1.3 mL of medium was added to each well and culture was performed for 16 days.
- AGP-3001S (registered trademark) manufactured by STREX was used to apply a hydrostatic pressure of 33.33 kPa, during the period from the 6th day to the 16th day from the start of the culture.
- Ly was added to the medium such that a final concentration is 25 ⁇ M, during the period from the 6th day to the 16th day from the start of the culture.
- the medium was cultured in ⁇ M2 for 4 days and then cultured in S10.
- ICI 182,780 (7 ⁇ ,17 ⁇ -[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol) (manufactured by Tocris Bioscience) which is an estrogen receptor antagonist was added during the period from 5th to 9th day after the start of culture such that a final concentration in the medium is 500 nM. About half of the medium was replaced with anew medium every other day. As a control, those cultured in the same manner in the presence of Ly without pressurization were also prepared.
- a tissue section of the gonad was prepared by using the same method as in (1) of Reference Example 1.
- tissue section of the gonad obtained in (3) was immunohistochemically stained using the same method as in (4) of Example 1.
- c and g are immunostaining images using an antibody against the MVH of the germ cell marker.
- d is an image in which a nuclear-staining image using DAPI is superimposed on the staining images in a to c.
- h is an image in which a nuclear-staining image using DAPI is superimposed on the staining images in e to g.
- a scale bar represents 10 ⁇ m.
- FIG. 8 A is a graph obtained by calculating a proportion of oocytes in which the transcription factor Foxo3a is localized in the nucleus, from the immunostaining image using the antibody against the transcription factor Foxo3a in FIG. 7 .
- FIG. 8 B is a graph obtained by calculating a proportion of oocytes in which the transcription factor Foxo3a is localized in a cytosol, from the immunostaining image using the antibody against the transcription factor Foxo3a in FIG. 7 .
- the gonad and a medium were prepared using the same method as in (1) of Example 1.
- the gonad were in vitro cultured using the same method as in (2) of Example 1 except that the gonad was cultured under the artificially pressurized condition and the low oxygen concentration condition.
- AGP-3001S registered trademark
- STREX was used to apply a hydrostatic pressure of 33.33 kPa.
- culturing was performed under a 5% oxygen concentration condition using APM30D manufactured by Astec.
- APM30D manufactured by Astec.
- controls (1) 3.5-day-old ovaries, (2) those similarly cultured under the artificially pressurized condition, and (3) those similarly cultured under the low oxygen concentration condition were also prepared.
- the gonad cultured in (2) were crushed to prepare a cell suspension. Then, the analysis was performed using a flow cytometer (model number: BD FACSAria III (648282B5), manufactured by BD Bioscience). Results are shown in FIG. 9 .
- the upper row shows a two-dimensional histogram of forward scattered light (FSC) indicating a cell size and fluorescence of CFP expressed under the control of the germ cell marker Stella.
- the lower row shows a histogram showing a distribution of FSC in CFP-expressing cells.
- the “Merge” at the right end of the lower row shows a histogram in which four histograms in the lower row are superposed.
- FSC forward scattered light
- the method of the present embodiment reproduces the environment in the living gonad and can differentiate the primordial germ cell into a primordial follicle.
- the method of the present embodiment it is possible to differentiate a primordial germ cell into a primordial follicle in vitro.
- the primordial follicle obtained by the method of the present embodiment is suitably used for, for example, an infertility treatment, efficient breeding of industrial animals, breeding of rare animals, investigation of causes of infertility, elucidation of a mechanism of menopausal diseases, and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
-
- Patent Document 1: PCT International Publication No. WO 2017/047799
-
- Non-Patent Document 1: Morohaku K. et al., “Complete in vitro generation of fertile oocytes from mouse primordial germ cells.”, Proc Natl Acad Sci, Vol. 113, No. 32, p9021-9026, 2016.
-
- (1) an oocyte is surrounded by flat granulosa cells;
- (2) a transcription factor having a function of maintaining follicle maturation in a resting phase is localized in a nucleus of the oocyte.
-
- (3) a diameter is 20 μm or smaller.
-
- (i) Function of inhibiting disruption of oocyte cysts in oocytes derived from primordial germ cells; and
- (ii) At least one function of inhibiting the formation of primordial follicles
-
- (1) an oocyte is surrounded by flat granulosa cells;
- (2) a transcription factor having a function of maintaining follicle maturation in a resting phase is localized in a nucleus of the oocyte.
-
- (3) a diameter is 20 μm or smaller.
Claims (9)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018117988 | 2018-06-21 | ||
| JP2018-117988 | 2018-06-21 | ||
| PCT/JP2019/021209 WO2019244581A1 (en) | 2018-06-21 | 2019-05-29 | Method for differentiating primordial germ cells into primordial follicles in vitro |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20210261922A1 US20210261922A1 (en) | 2021-08-26 |
| US12054747B2 true US12054747B2 (en) | 2024-08-06 |
Family
ID=68982696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/253,518 Active 2041-02-17 US12054747B2 (en) | 2018-06-21 | 2019-05-29 | Method of differentiating primordial germ cell into primordial follicle in vitro |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12054747B2 (en) |
| EP (1) | EP3812455A4 (en) |
| JP (1) | JP7341501B2 (en) |
| CN (1) | CN112352045B (en) |
| WO (1) | WO2019244581A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230144683A1 (en) * | 2021-11-09 | 2023-05-11 | Gameto, Inc | Platform and method for determining critical transcription factors (tf) for tf-based human induced pluripotent stem cell (hipsc) differentiation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7671027B2 (en) * | 2002-12-27 | 2010-03-02 | Preglem S.A. | Use of GnRH agonists to support the luteal phase during infertility treatment |
| US20140314762A1 (en) * | 2011-12-14 | 2014-10-23 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation of Ovarian Follicle Development and Oocyte Maturation |
| WO2017013412A1 (en) * | 2015-07-17 | 2017-01-26 | Sage & Time Llp | Gas conditioning process and system for extracting a condensable vapour from a supplied gas |
| WO2017047799A1 (en) | 2015-09-17 | 2017-03-23 | 学校法人東京農業大学 | Culture method for differentiating primordial germ cells into functionally mature oocytes |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6892101B2 (en) | 2017-01-27 | 2021-06-18 | 株式会社タカゾノ | Drug containment device |
-
2019
- 2019-05-29 WO PCT/JP2019/021209 patent/WO2019244581A1/en not_active Ceased
- 2019-05-29 JP JP2020525417A patent/JP7341501B2/en active Active
- 2019-05-29 EP EP19822475.0A patent/EP3812455A4/en active Pending
- 2019-05-29 US US17/253,518 patent/US12054747B2/en active Active
- 2019-05-29 CN CN201980040407.8A patent/CN112352045B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7671027B2 (en) * | 2002-12-27 | 2010-03-02 | Preglem S.A. | Use of GnRH agonists to support the luteal phase during infertility treatment |
| US20140314762A1 (en) * | 2011-12-14 | 2014-10-23 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation of Ovarian Follicle Development and Oocyte Maturation |
| WO2017013412A1 (en) * | 2015-07-17 | 2017-01-26 | Sage & Time Llp | Gas conditioning process and system for extracting a condensable vapour from a supplied gas |
| WO2017047799A1 (en) | 2015-09-17 | 2017-03-23 | 学校法人東京農業大学 | Culture method for differentiating primordial germ cells into functionally mature oocytes |
| US20180251729A1 (en) * | 2015-09-17 | 2018-09-06 | Tokyo University Of Agriculture Educational Corporated | Culture method for differentiating primordial germ cells into functionally mature oocytes |
Non-Patent Citations (9)
| Title |
|---|
| Extended European Search Report for European Patent Application No. 19822475.0, mailed Feb. 21, 2022. |
| Hayashi et al., "Reconstitution of the Mouse Germ Cell Specification Pathway in Culture by Pluripotent Stem Cells", Cell, Jun. 2011, 146(4): 519-532. |
| Hikabe et al., "Reconstitution in vitro of the entire cycle of the mouse female germline", Nature 539:299-303 (2016). |
| Hirao, "oocytes expulsion", Tatsumi University Journal 29:112-113 (2017). |
| International Search Report for International Application No. PCT/JP2019/021209 mailed Aug. 20, 2019, 4 pages. |
| Kanako Morohakua et al., Complete in vitro generation of fertile oocytes from mouse primordial germ cells, PNAS, vol. 113, No. 32, 9021-9026. (2016). |
| Nagamatsu et al., "Mechanical stress accompanied with nuclear rotation is involved in the dormant state of mouse oocytes", Science Advances, Jun. 26, 2019, 5: eaav9960, XP055890259, Retrieved from url: https://www.science.org/doi/epdf/10.1126/sciadv.aav9960. |
| Pilar Lopez-Iglesias et al., Hypoxia Induces Pluripotency in Primordial Germ Cells by HIF1α Stabilization and Oct4 Deregulation, Antioxidants & Redox Signaling, vol. 22, No. 3, pp. 205-223. (2015). |
| Shimamoto et al., "Hypoxia induces the dormant state in oocytes through expression of Foxo3", Proceedings of the National Academy of Sciences, Jun. 18, 2019, 116(25): 12321-12326. |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7341501B2 (en) | 2023-09-11 |
| US20210261922A1 (en) | 2021-08-26 |
| JPWO2019244581A1 (en) | 2021-06-24 |
| EP3812455A4 (en) | 2022-03-23 |
| CN112352045A (en) | 2021-02-09 |
| WO2019244581A1 (en) | 2019-12-26 |
| EP3812455A1 (en) | 2021-04-28 |
| CN112352045B (en) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6905714B2 (en) | Culture method for differentiating primordial germ cells into functionally mature oocytes | |
| Takehara et al. | The restorative effects of adipose-derived mesenchymal stem cells on damaged ovarian function | |
| Virant-Klun | Postnatal oogenesis in humans: a review of recent findings | |
| Wang et al. | Genetic studies in mice directly link oocytes produced during adulthood to ovarian function and natural fertility | |
| Gerri et al. | A conserved role of the Hippo signalling pathway in initiation of the first lineage specification event across mammals | |
| Khajavi et al. | Role of somatic testicular cells during mouse spermatogenesis in three-dimensional collagen gel culture system | |
| Hu et al. | Characterization of female germ‐like cells derived from mouse embryonic stem cells through expression of GFP under the control of Figla promoter | |
| JP2023107982A (en) | Method for inducing immature oocytes and method for producing mature oocytes | |
| Kaanta et al. | Evidence for a multipotent mammary progenitor with pregnancy-specific activity | |
| Sauvegarde et al. | Dynamic pattern of HOXB9 protein localization during oocyte maturation and early embryonic development in mammals | |
| Shi et al. | Efficient generation of bone morphogenetic protein 15-edited Yorkshire pigs using CRISPR/Cas9 | |
| JP4980211B2 (en) | Cell isolation method | |
| US20040096971A1 (en) | Thymic epithelial progenitor cells and uses thereof | |
| US12054747B2 (en) | Method of differentiating primordial germ cell into primordial follicle in vitro | |
| US20160192626A1 (en) | Method For Creating Endometriotic Cells And Endometriosis Model Animal | |
| Wojtanowicz-Markiewicz et al. | Expression of Selected Connexin and Aquaporin Genes and Real‐Time Proliferation of Porcine Endometrial Luminal Epithelial Cells in Primary Culture Model | |
| Jung et al. | Study on the in-vitro culture method for normal embryonic cell development of porcine parthenogenetic embryos | |
| Aerts et al. | Xenotransplantation by injection of a suspension of isolated preantral ovarian follicles and stroma cells under the kidney capsule of nude mice | |
| US20220315889A1 (en) | Materials and methods for generating functional oocytes | |
| Zhang et al. | Progress in germline stem cell transplantation in mammals and the potential usage | |
| Nabulindo | SPERMATOGONIAL STEM CELL CULTURE, TRANSFECTION, AND INTRA-TESTICULAR TRANSPLANTATION AS A PRELIMINARY TOOL TOWARDS OBTAINING GENETIC MODIFICATION OF KENYAN GALLA GOAT | |
| Kruger | Interactions Between Hippo, FGF, and TGFβ Signaling Regulate Morphogenesis of Early Mouse Embryos | |
| AU2017201404B2 (en) | Compositions And Methods For Autologous Germline Mitochondrial Energy Transfer | |
| WO2024220987A1 (en) | Ipsc-based restoration of ovarian function | |
| Madich et al. | Contribution of GFP Expressing Dermal Papillae Cells to the Formation of Chimeric Embryos and their Survival in Uterine Environment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| AS | Assignment |
Owner name: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAGAMATSU, GO;NISHIMURA, YOHEI;SHIMAMOTO, SO;AND OTHERS;SIGNING DATES FROM 20201208 TO 20201218;REEL/FRAME:054721/0694 |
|
| FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
| ZAAA | Notice of allowance and fees due |
Free format text: ORIGINAL CODE: NOA |
|
| ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
| ZAAA | Notice of allowance and fees due |
Free format text: ORIGINAL CODE: NOA |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |